Exposure to potential cyp450 pharmacokinetic drug-drug interactions among osteoarthritis patients: Incremental risk of multiple prescriptions

Joseph V. Pergolizzi, Sumedha A. Labhsetwar, R. Amy Puenpatom, Seongjung Joo, Rami Ben-Joseph, Kent H. Summers

Research output: Contribution to journalArticle

Abstract

Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system experience a drug-drug exposure (DDE), which puts them at risk for a potential pharmacokinetic drug-drug interaction (DDI), defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Any patient subjected to a DDE is at risk for a potentially serious DDI, the epidemiology of which has not been thoroughly studied. Many drugs are metabolized primarily via the CYP450 enzyme system, including certain opioids used to manage moderate to severe chronic pain. We conducted a retrospective analysis of a large commercial claims database and a Medicare database to assess the prevalence of DDEs among patients with osteoarthritis taking CYP450-metabolized opioids. The overall prevalence of DDEs in this population was 26%, with females more likely to experience DDEs than males (28.4% vs. 21.0%, respectively). The number of unique concurrent prescriptions at baseline, gender, age, and Charlson Comorbidity Index were statistically significant predictors of DDEs (P

Original languageEnglish (US)
Pages (from-to)325-336
Number of pages12
JournalPain Practice
Volume11
Issue number4
DOIs
StatePublished - Jul 2011

Fingerprint

Drug Interactions
Osteoarthritis
Prescriptions
Pharmacokinetics
Dichlorodiphenyl Dichloroethylene
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Opioid Analgesics
Databases
Medicare
Chronic Pain
Comorbidity
Epidemiology

Keywords

  • Analgesics
  • CYP450
  • Drug-drug interactions
  • Opioid
  • Osteoarthritis

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Exposure to potential cyp450 pharmacokinetic drug-drug interactions among osteoarthritis patients : Incremental risk of multiple prescriptions. / Pergolizzi, Joseph V.; Labhsetwar, Sumedha A.; Puenpatom, R. Amy; Joo, Seongjung; Ben-Joseph, Rami; Summers, Kent H.

In: Pain Practice, Vol. 11, No. 4, 07.2011, p. 325-336.

Research output: Contribution to journalArticle

Pergolizzi, Joseph V. ; Labhsetwar, Sumedha A. ; Puenpatom, R. Amy ; Joo, Seongjung ; Ben-Joseph, Rami ; Summers, Kent H. / Exposure to potential cyp450 pharmacokinetic drug-drug interactions among osteoarthritis patients : Incremental risk of multiple prescriptions. In: Pain Practice. 2011 ; Vol. 11, No. 4. pp. 325-336.
@article{4bc664f9dd7a42ef8ad37a01353588f8,
title = "Exposure to potential cyp450 pharmacokinetic drug-drug interactions among osteoarthritis patients: Incremental risk of multiple prescriptions",
abstract = "Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system experience a drug-drug exposure (DDE), which puts them at risk for a potential pharmacokinetic drug-drug interaction (DDI), defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Any patient subjected to a DDE is at risk for a potentially serious DDI, the epidemiology of which has not been thoroughly studied. Many drugs are metabolized primarily via the CYP450 enzyme system, including certain opioids used to manage moderate to severe chronic pain. We conducted a retrospective analysis of a large commercial claims database and a Medicare database to assess the prevalence of DDEs among patients with osteoarthritis taking CYP450-metabolized opioids. The overall prevalence of DDEs in this population was 26{\%}, with females more likely to experience DDEs than males (28.4{\%} vs. 21.0{\%}, respectively). The number of unique concurrent prescriptions at baseline, gender, age, and Charlson Comorbidity Index were statistically significant predictors of DDEs (P",
keywords = "Analgesics, CYP450, Drug-drug interactions, Opioid, Osteoarthritis",
author = "Pergolizzi, {Joseph V.} and Labhsetwar, {Sumedha A.} and Puenpatom, {R. Amy} and Seongjung Joo and Rami Ben-Joseph and Summers, {Kent H.}",
year = "2011",
month = "7",
doi = "10.1111/j.1533-2500.2010.00438.x",
language = "English (US)",
volume = "11",
pages = "325--336",
journal = "Pain Practice",
issn = "1530-7085",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Exposure to potential cyp450 pharmacokinetic drug-drug interactions among osteoarthritis patients

T2 - Incremental risk of multiple prescriptions

AU - Pergolizzi, Joseph V.

AU - Labhsetwar, Sumedha A.

AU - Puenpatom, R. Amy

AU - Joo, Seongjung

AU - Ben-Joseph, Rami

AU - Summers, Kent H.

PY - 2011/7

Y1 - 2011/7

N2 - Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system experience a drug-drug exposure (DDE), which puts them at risk for a potential pharmacokinetic drug-drug interaction (DDI), defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Any patient subjected to a DDE is at risk for a potentially serious DDI, the epidemiology of which has not been thoroughly studied. Many drugs are metabolized primarily via the CYP450 enzyme system, including certain opioids used to manage moderate to severe chronic pain. We conducted a retrospective analysis of a large commercial claims database and a Medicare database to assess the prevalence of DDEs among patients with osteoarthritis taking CYP450-metabolized opioids. The overall prevalence of DDEs in this population was 26%, with females more likely to experience DDEs than males (28.4% vs. 21.0%, respectively). The number of unique concurrent prescriptions at baseline, gender, age, and Charlson Comorbidity Index were statistically significant predictors of DDEs (P

AB - Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system experience a drug-drug exposure (DDE), which puts them at risk for a potential pharmacokinetic drug-drug interaction (DDI), defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Any patient subjected to a DDE is at risk for a potentially serious DDI, the epidemiology of which has not been thoroughly studied. Many drugs are metabolized primarily via the CYP450 enzyme system, including certain opioids used to manage moderate to severe chronic pain. We conducted a retrospective analysis of a large commercial claims database and a Medicare database to assess the prevalence of DDEs among patients with osteoarthritis taking CYP450-metabolized opioids. The overall prevalence of DDEs in this population was 26%, with females more likely to experience DDEs than males (28.4% vs. 21.0%, respectively). The number of unique concurrent prescriptions at baseline, gender, age, and Charlson Comorbidity Index were statistically significant predictors of DDEs (P

KW - Analgesics

KW - CYP450

KW - Drug-drug interactions

KW - Opioid

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=79960159735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960159735&partnerID=8YFLogxK

U2 - 10.1111/j.1533-2500.2010.00438.x

DO - 10.1111/j.1533-2500.2010.00438.x

M3 - Article

C2 - 21199317

AN - SCOPUS:79960159735

VL - 11

SP - 325

EP - 336

JO - Pain Practice

JF - Pain Practice

SN - 1530-7085

IS - 4

ER -